Medicare Contractor Novitas Schedules Expert Panel

9 February 2026
MEDICARE CONTRACTOR NOVITAS SCHEDULES EXPERT PANEL
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) notes
its Medicare Administrative Contractor (MAC) Novitas has confirmed the scheduling of its
planned Contractor Advisory Committee (CAC) to consider the evidence for urine biomarkers
in patients with hematuria.
The opinions expressed during the meeting, which is scheduled to take place from 6:00pm on
19 February 2026, US ET (12:00pm Friday 20 February 2026 NZST), are expected to have
an influence over the language Novitas uses in any draft Local Coverage Determination (LCD)
covering Medicare reimbursement of Cxbladder that is published following the meeting.
The WebEx meeting is estimated to run for two hours and is public to the public by registering
at the link below.
https://fcso.webex.com/weblink/register/red3f833b75a2f3922d04ada5d71a6aee
Given the significance of the CAC, Pacific Edge expects its shares to enter a trading halt
ahead of the meeting that is expected to last until the company provides an announcement to
investors giving context to the matters covered at the CAC. The company expects to make
this announcement ahead of the market open on Monday 23 February 2026 (NZST).
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the
way in the development and commercialization of bladder cancer diagnostic and prognostic
tests for patients presenting with hematuria or surveillance of recurrent disease.
Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests
globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the
USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with microhematuria and those being monitored for
recurrent disease. The tests help improve the overall patient experience, while prioritizing time
and clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
25 peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned
studies designed to generate further clinical utility evidence.

2
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and
South America. In the US, the test has been used by over 5,000 urologists who have ordered
more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the
population via public healthcare and all residents have the option of buying the test online.